IFN-α2b对慢性乙肝患者抗病毒及免疫调节作用

Negative Effect of IFN-α2b on HBV-DNA and CD25 in the Patients with Chronic Hepatitis B

目的探讨IFN-α2b对慢性乙肝患者抗病毒效果及对CD25的免疫调节作用。方法选择160例慢性乙肝患者(轻度93例,中度67例),随机分为IFN和常规治疗组,用生物素-链霉亲和素(BSA)法和Real-time PCR法分别动态检测PHA诱导前后CD25和CD25 mRNA的表达水平,PCR法动态检测患者治疗前后HBV-DNA水平。结果轻、中度组患者经干扰素治疗后,静息态和诱导态CD25表达水平逐渐升高,其CD25 mRNA含量亦升高。第3疗程后,轻、中度组中以干扰素治疗者CD25表达水平与同期常规治疗者相比,差异有显著性(P<0.05)。CD25 mRNA表达水平与CD25的表达具有平行性。IFN治疗者血清和PBMC内HBV-DNA阴转率均高于常规治疗者(P<0.05或P<0.01)。结论IFN-α2b对血清和PBMC内HBV-DNA均有较好阴转效果,阴转率明显高于常规治疗者。IFN-α2b可诱导T细胞活化,CD25表达水平增加,通过免疫调节发挥抗病毒作用。

OBJECTIVE To explore the effect of IFN-α2b on CD25 and HBV in the patients with chronic hepatitis B. METHODS The total of 160 chronic hepatitis B patients （ slight 93 and moderate 67 ） were randomly divided into two groups and treated with IFN-α2b and routine medicine respectively, and their levels of CD25 and its mRNA before and after being stimulated with PHA were dynamically detected by biotin-streptavidin （BSA） and Real-time PCR,respectively. RESULTS The expression of CD25 and its mRNA was increased after the treatment of IFN-α2b. After the treatment of IFN-α2b for three courses of treatment, there was significant difference between IFN （light and moderate） group and routine medicine group （P 〈 0. 05）. In our study,the expression of CD25 mRNA was paralleled with that of CD25. It had been that the HBV-DNA in PBMC and serum in the patients treated with IFN （light and moderate） were improved compared with the patients treated with routine medicine （P 〈 0. 01 and P 〈 0. 05 ）. CONCLUSION IFN- α2b has better therapeutic effect on HBV-DNA in serum and PBMC than that of routine therapy. CD25 and its mRNA can be induced by IFN-α2b so that a lot of T lymphocytes can be activated and play key role against HBV-DNA in hosts.